Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-TIMELESS mRNAs with seed-region complementarity refers to a diverse set of messenger RNA (mRNA) transcripts that are unintentionally targeted by RNA interference (RNAi) reagents, such as siRNAs or shRNAs, designed to silence the TIMELESS gene. This phenomenon occurs because the seed region of the small RNA, typically nucleotides 2 through 7 or 8, can recognize and bind to complementary sequences within the 3' untranslated regions (UTRs) of many different mRNAs, not just the intended target (Putzbach et al., 2017, Nature Communications). This mechanism is the basis for seed-mediated off-target effects, which can lead to significant changes in the cellular transcriptome and proteome independent of the primary target's knockdown (Gao et al., 2018, Nature Communications). In the context of TIMELESS, research has shown that certain siRNAs can trigger a potent form of cell death known as Death Induced by Survival gene Elimination (DISE) by silencing a network of survival-related mRNAs through their seed regions (Murmann et al., 2018, Oncotarget). While TIMELESS itself is a recognized target in oncology due to its roles in circadian regulation and DNA replication stress, these non-TIMELESS transcripts represent a source of experimental noise and potential toxicity. Understanding these interactions is crucial for the design of highly specific RNAi therapeutics and for interpreting the biological outcomes of TIMELESS knockdown in research settings. Consequently, these mRNAs are viewed as off-targets that must be carefully screened during the development of RNA-based medicines to avoid unintended adverse effects.
RNA interference-mediated silencing of non-target transcripts through seed-sequence complementarity in the 3' UTR.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-TIMELESS mRNAs with seed-region complementarity.